Introduction {#s1}
============

Coronary artery disease (CAD) is a common complex disorder resulting from both genetic and environmental influences [@pone.0031406-Topol1], [@pone.0031406-Yamada1], and it has become a major cause of death and disability in China. The role of genetic alterations and their impact on CAD susceptibility remains unclear and has attracted more attention. In the past three decades, genetic association studies and genome-wide linkage scans have revealed a considerable number of candidate loci and genes for CAD and myocardial infarction (MI) [@pone.0031406-Hartiala1]--[@pone.0031406-He1], but results are not often reproducible [@pone.0031406-Tsantes1]--[@pone.0031406-Scheuner1].

In 2003, a 7-amino acid deletion, caused by a 21-base pair (bp) coding sequence deletion in exon 11 of the myocyte enhancer factor 2A (*MEF2A*) gene, was reported as a causative mutation in a single large CAD/MI family of Scandinavia ancestry [@pone.0031406-Wang1]. *In vitro* functional analysis indicated that the 21-bp deletion disrupted the nuclear localization of mature protein and decreased *MEF2A*-induced transcriptional activation. Thus this genetic imperfection might lead to a defective or abnormal vascular endothelium, which could promote the genesis of atherosclerotic plaque or thrombosis and influence the whole process of atherogenesis [@pone.0031406-Wang1]. Subsequently, the same researchers discovered three functional variants (Asn263Ser, Pro279Leu and Gly283Asp) in exon 7 in approximately 2% of the affected population, but none in unaffected individuals [@pone.0031406-Bhagavatula1]. Thence, *MEF2A* gene has been considered as the first CAD-causing gene to be identified.

The genomic sequence of *MEF2A* gene is highly polymorphic. It is thus of added interest to detect which or how many *MEF2A* genetic variants might have functional potential to affect the final bioavailability of *MEF2A*, and further the development of CAD. In fact, many case-control studies have attempted to investigate the unequivocal effects of *MEF2A* gene on CAD, especially its exon 11, claimed as the most polymorphic locus harboring various substitution and insertion/deletion (indel) polymorphisms such as a common variant (CAG)~n~ polymorphism. However, the results have been inconsistent [@pone.0031406-Gonzlez1]--[@pone.0031406-Guella1].

With the improved genotyping technologies and the completion of the human HapMap project, Genome-Wide Association Studies (GWASs) have been developed as an important approach in genetic research. Thus far, a large number of candidate loci conferring risk of or protection from common complex diseases such as CAD have been proposed [@pone.0031406-Hirschhorn1]--[@pone.0031406-Patel1]. Nonetheless, neither the *MEF2A* locus on chromosome 15q26 nor its adjacent region has been identified in any of the previous GWASs, thus generating debate over the nature of *MEF2A* genetic contribution to individual susceptibility to CAD.

To elucidate the relationship between *MEF2A* gene and its effect on CAD risk, we focused on its exon 11, the highly polymorphic and controversial region, and established a well-characterized case-control study of 1045 sporadic CAD patients and 1008 controls with normal coronary arteries. In addition, we reviewed all available studies reported in the literature to examine the association of the common (CAG)~n~ polymorphism and the rare 21-bp deletion with CAD, and to assess whether variations in study design and study population ethnicity could lead to potential biases and be the sources of between-study heterogeneity.

Materials and Methods {#s2}
=====================

Case-control study {#s2a}
------------------

### Ethics Statement {#s2a1}

Approval to undertake this study was granted by the Ethics Review Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and was conducted according to the Declaration of Helsinki Principles. Written informed consents were obtained from each participant at enrollment.

### Study population {#s2a2}

This was a hospital-based case-control study including a total of 2053 unrelated Han Chinese admitted to Ruijin Hospital, Shanghai Jiao Tong University School of Medicine when they were experiencing various symptoms or for a medical checkup from January 2006 to September 2009. All participants underwent coronary angiography and were divided into CAD group and control group according to their angiographic results.

The CAD group contained 1045 sporadic patients aged 65.49±9.83 years, and the diagnosis of CAD was determined angiographically based on the presence of more than 70% stenosis in at least one of the three major coronary arteries or major branches. Patients with simple spasm of coronary arteries, myocardial bridge or other non-coronary atherosclerotic lesions were excluded. The remaining participants (n = 1008), aged 60.23±10.49 years, had normal coronary arteries (NCA) on angiography, formed the control group.

All patients with the 21-bp deletion were followed up every year in a special CAD clinic. At each visit, clinical manifestations and echocardiography were recorded. Adverse events (e.g. hospitalization, cardiac dysfunction, percutaneous coronary intervention, coronary artery bypass grafting, or death) were reported during the visit or through telephone conversation with the patients or their family members. Two trained physicians independently reviewed all medical notes, including emergency department visit forms and hospital medical records.

### Screening for variations in *MEF2A* exon 11 {#s2a3}

Blood samples (5 ml) were drawn and genomic DNA was extracted from peripheral blood leukocytes by standard phenol-chloroform extraction. To assess the distribution patterns of the structural variations of *MEF2A* exon 11 in this cohort study, we sequenced the entire exon 11 using the direct DNA sequencing method in all 2053 subjects. Primers were designed by the Primer3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3>) according to reference sequence (NM_005920.2). In detail, the sequence of the forward primer was 5′-gca gag gta ctt gca agc cat ctg-3′ and the reverse was 5′-ggt cgg cca agc aca att gga gaa-3′. The sequencing primer was 5′-caa gca caa ttg gag aat gga-3′. Sequences were analyzed using an ABI Prism BigDye Terminator Cycle Sequencing Kit on an ABI Prism 3700 sequencer, version 3.1 (Applied Biosystems, Foster City, CA, USA), as described in detail in [Text S1](#pone.0031406.s001){ref-type="supplementary-material"}.

Systematic review and meta-analysis {#s2b}
-----------------------------------

### Data sources and search strategies {#s2b1}

We collected information via two international searching engines, *viz.* PubMed and Excerpta Medica Database (EMBASE), and two Chinese searching engines, *viz.* Wanfang database (<http://www.wanfangdata.com.cn>) and China Biological Medicine (CBM) (<http://sinomed.imicams.ac.cn/index.jsp>) with the last update on July 31, 2011. We restricted search results to papers published in English or Chinese. We combined the subject terms of 'coronary artery disease or coronary disease or arteriosclerosis or atherosclerosis or myocardial infarction or angina pectoris' and 'myocyte enhancer factor 2A' with either 'gene', 'variation', 'variant', 'mutation', 'polymorphism' or 'allele', which were all MeSH (Medical Subject Headings in the US National Library of Medicine) terms. The "related articles" in the MEDLINE option as well as reference lists of all retrieved studies were also checked for citations of other relevant publications that were not identified initially. All studies were considered potentially eligible if they aimed to investigate the relationship between *MEF2A* genetic polymorphisms and CAD risk. If there were multiple publications from the same study group, the most complete and recent results were extracted. Search results were limited to studies performed in human subjects without country restrictions and ethnic restrictions.

### Inclusion/exclusion criteria {#s2b2}

We enrolled all prevalent case-control or nested case-control or cross-sectional studies in this meta-analysis regardless of sample size, if 1) they explored the association of *MEF2A* genetic polymorphisms with CAD/MI, 2) genotyping had been performed by using validated methods, and 3) they provided the sufficient information on genotype/allele counts or frequencies for estimating odds ratio (OR) and 95% confidence interval (95% CI). We calculated the effect estimate against healthy subjects/NCA controls.

### Data extraction {#s2b3}

Data were extracted independently and entered into separate databases by two authors (Y. Liu and W. Niu) from each qualified study: first author\'s last name, publication date, population ethnicity, study design, diagnostic criteria, genotyping methods, baseline characteristics of the study population, such as age, gender, history of hypertension and diabetes mellitus, if available, and the number of persons with different alleles in cases and controls and available subgroups. Discrepancies between the two databases were identified by comparison. A third author (W. Jin) checked for them and a consensus was reached after discussion. For consistency, continuous variables such as age were uniformly expressed as mean ± standard deviation (S.D.)

### Statistical analysis {#s2b4}

For our case-control study, database management and statistical calculation were conducted using SPSS version 13.0 (SPSS Inc., Chicago, Illinois, USA). The Student\'s *t*-test for continuous variables and the *χ^2^*-test for categorical ones were used to test differences between cases and controls, OR of CAD risk and their 95% CI were calculated as well.

Hardy-Weinberg equilibrium calculations were performed with the Arlequin program (<http://anthro.unige.ch/software/arlequin>). The Haplo.stats package (version 1.4.0) in the R statistical computing software (<http://www.r-project.org>) was used to analyze haplotype-based association study. Two-tailed *P*\<0.05 was accepted as statistically significant.

In the following meta-analysis, pooled association relating (CAG)~n~ polymorphism to CAD risk was performed by the Review Manager software (version 5.0.19; <http://www.cc-ims.net/revman/download>). Using the most common type (CAG)~9~ allele as a reference, comparisons of other (CAG)~n~ alleles between cases and controls were expressed in the form of OR and 95% CI. The allele effects were estimated using the model-free approach, where no assumption about genetic models was required. In addition, stratification analyses were conducted to seek more narrowly drawn subsets of the studies such as different genotyping methods, population origins and study designs. We implemented the random-effects model using the method of DerSimonian and Laird, instead of fixed-effects model, to bring the individual effect-size estimates together, and the estimate of heterogeneity was analyzed by the Mantel-Haenszel method [@pone.0031406-Cohn1]--[@pone.0031406-Higgins1].

The presence of between-study heterogeneity across all eligible comparisons was calculated using the *χ^2^*-based Cochrane\'s Q statistic with statistical significance at the level of 0.10 as this statistic has proven to have poor power if there are few studies [@pone.0031406-Higgins1], [@pone.0031406-Lau1]. Besides, the *I^2^* statistic was documented for the percentage of the observed between-study variability due to heterogeneity rather than chance with the ranges of 0--100% (*I^2^* = 0--25%, no heterogeneity; *I^2^* = 25--50%, moderate heterogeneity; *I^2^* = 50--75%, large heterogeneity; *I^2^* = 75--100%, extreme heterogeneity) [@pone.0031406-Higgins1].

Finally, publication bias was assessed by the fail-safe number (*N~fs~*) of each meta-analysis [@pone.0031406-Einarson1]. If the *N~fs~* was smaller than the number of observed studies for a polymorphism, it is believed that the meta-result might have a significant publication bias. In this study, the *N~fs~* significance was established at *P*\<0.05 (*N~fs0.05~* = (ΣZ/1.64)^2^−*k*; where *k* is the number of articles included in each meta-analysis).

Results {#s3}
=======

Clinical characteristics of our study population {#s3a}
------------------------------------------------

The clinical characteristics of our study population are shown in [Table S1](#pone.0031406.s002){ref-type="supplementary-material"}. Compared with NCA controls, CAD patients were older (*P*\<0.001) and more often of the male gender (*P*\<0.001). As expected, the CAD group had a higher prevalence of conventional cardiovascular risk factors, including diabetes and dyslipidemia (*P*\<0.05). They had higher serum levels of fasting glucose, total cholesterol, triglycerides, and low density lipoprotein-cholesterol, and lower levels of high density lipoprotein-cholesterol. However, the morbidity of hypertension was similar between the two groups.

Genetic information on our case-control study {#s3b}
---------------------------------------------

Eight variants were identified by sequencing the entire exon 11 in 2053 unrelated Chinese individuals ([Table 1](#pone-0031406-t001){ref-type="table"}). No significant deviation from the Hardy-Weinberg equilibrium was detected for each polymorphism in both CAD patients and NCA controls.

10.1371/journal.pone.0031406.t001

###### Genetic variations in *MEF2A* gene exon 11 discovered by sequencing in our study population.

![](pone.0031406.t001){#pone-0031406-t001-1}

  Categories             Variants             AA code[1](#nt101){ref-type="table-fn"}                      MAF (allele frequency, %)                       *P value; OR \[95% CI\]*  
  ------------ ----------------------------- ----------------------------------------- ------------------------------------------------------------------ -------------------------- --------------------------------
  STR              (CAG)~n~ (1257--1290)                (Q)~n~ (n = 4--15)              More details in [Table 4](#pone-0031406-t004){ref-type="table"}.                             
  Deletion           CCG (1291--1293)            P deletion (n = 4 or 5, 431/432)                                   111(5.3)                                      109 (5.4)           0.892; 1.019 \[0.777, 1.337\]
                     CCA (1297--1299)                  P deletion (433/434)                                            0                                           1(0.05)           
                21-bp deletion (1303--1337)       QPPQPQP deletion (434--446 AA)                                     5(0.2)                                           0              
  SNP                     A1299G                               P433P                                                1(0.05)                                        1(0.05)            0.980; 1.036 \[0.065, 16.571\]
                          C1303T                               P435S                                                9 (0.4)                                        5 (0.2)            0.315; 0.574 \[0.192, 1.717\]
                          G1305A                               P435P                                                92 (4.4)                                       91 (4.5)           0.867; 0.975 \[0.725, 1.312\]
                          G1353T                               G443G                                               693 (33.2)                                     689 (34.2)          0.490; 1.047 \[0.920, 1.191\]

Q = Gln; P = Pro; S = Ser; G = Gly.

STR: short tandem repeat polymorphism; SNP: single nucleotide polymorphism; AA: amino acid; MAF: minor allele frequency; OR: odds ratio; 95%CI: 95% confidence interval.

The number of the CAG triplet repeats (polyglutamine tandem repeats, *(Q)~n~*) spanned from 4 to15, and the majority of individuals had 9--11 repeats. Shown in [Table 2](#pone-0031406-t002){ref-type="table"} are the allele distributions of (CAG)~n~ polymorphism. No statistical significance was observed (*P* = 0.347) for the allelic association of this polymorphism with CAD, and the distribution of genotypes was also similar in two groups (data not shown).

10.1371/journal.pone.0031406.t002

###### The baseline characteristics of all the studies relevant to (CAG)~n~ polymorphism in this meta-analysis.

![](pone.0031406.t002){#pone-0031406-t002-2}

  Ref. no         Study        Years          Ethnicity                Status                         Enrollment criteria                      Genotyping methods      Study size    Cases (allele frequencies, %)   Controls (allele frequencies, %)   *P value*                                                                                                                     
  --------- ----------------- ------- -------------------------- ------------------ -------------------------------------------------------- ----------------------- -------------- ------------------------------- ---------------------------------- ----------- ----------- ----------- ------------------------------------------ ----------- ----------- ------------ ---------- --------
  17           Weng et al.     2005        White (Canadian)       premature CAD/MI   Angiography confirmed CAD (\>50% stenosis), MI or CABG   Symptom investigation     Sequence                  287                              296                  197(32.8)   76(12.7)    292(48.7)    9(1.5)[1](#nt104){ref-type="table-fn"}    217(36.2)   80(13.3)    288(48.0)     7(1.2)    0.787
  31           Yuan et al.     2006    Asian (southern Chinese)        CAD/MI        Angiography confirmed CAD (\>50% stenosis), MI or CABG    Normal angiography       PCR-SSCP                  175                              228                  85(24.3)    66(18.9)    185(52.9)   14(4.0)[2](#nt105){ref-type="table-fn"}    106(23.2)   85(18.6)    246(53.9)    19(4.2)    0.985
  13         González et al.   2006        White (Spanish)               MI              Angiography confirmed CAD (\>30% stenosis), MI       Symptom investigation     Sequence                  211                              301                  136(32.2)   68(16.1)    216(51.2)    2(1.0)[3](#nt106){ref-type="table-fn"}    184(30.6)   97(16.1)    316(52.5)    5 (0.8)    \>0.05
  14           Han et al.      2007    Asian (Northern Chinese)        CAD/MI        Angiography confirmed CAD (\>50% stenosis), CABG or MI    Normal angiography       PCR-SSCP                  378                              348                  276(36.5)   158(20.9)   306(40.5)   16(2.1)[4](#nt107){ref-type="table-fn"}    158(22.7)   146(21.0)   362(52.0)    30(4.3)    0.001
  32          Gulec et al.     2008              Turk               premature MI                               MI                             Symptom investigation     PCR-SSCP                  69                                87                  70(51.0)       \_       62(44.5)     6(4.5)[5](#nt108){ref-type="table-fn"}    58(33.5)       \_       98 (56.0)    18(10.5)   \>0.05
  33           Lieb et al.     2008         White (German)          premature MI                               MI                             Symptom investigation     PCR-SSCP                  543                              1190                 393(36.2)   164(15.1)   510(47.0)                   19(1.7)                    865(36.3)   350(14.7)   1132(47.6)   33(1.4)    0.800
  18           Hsu et al.      2009       Asian (Taiwanese)            CAD/MI            Angiography confirmed CAD (\>50% stenosis), MI       Symptom investigation   MALDI-TOF MS                258                              258                  209(40.5)   108(20.9)   166(32.2)   33(6.4)[6](#nt109){ref-type="table-fn"}    180(34.9)   119(23.1)   189(36.6)    28(5.4)    0.179
  19           Dai et al.      2010    Asian (Northern Chinese)         CAD                Angiography confirmed CAD (≥75% stenosis)           Normal angiography       Sequence                  835                              304                  675(40.4)   319(19.1)   551(33.0)   125(7.5)[7](#nt110){ref-type="table-fn"}   254(41.8)   110(18.1)   213(35.0)    31(5.1)    0.052
               This study              Asian (Southern Chinese)        CAD/MI              Angiography confirmed CAD (≥70% stenosis)           Normal angiography       Sequence                 1045                              1008                 812(38.9)   458(21.9)   670(32.1)   150(7.2)[8](#nt111){ref-type="table-fn"}   809(40.1)   434(21.5)   646(32.0)    127(6.3)   0.374

CAD: coronary artery disease; MI: myocardial infarction; PTCA: percutaneous coronary angioplasty; CABG: coronary artery bypass grafting; PCR: polymerase chain reaction; SSCP: single strand conformational polymorphism analysis; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 5--8, 12, or 13 repeats.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 4, 7 or 8 repeats.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 6, 7, 8, 12, or 13 repeats..

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 5, 7, 8, or 12 repeats.

Number of (CAG)~n~ repeats: other, alleles with 5, 6, or 7 repeats.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 4, 5, 7, 8, 12--15 repeats.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 4, 5, 7, 8, 12, 14, or 15 repeats.

Number of (CAG)~n~ repeats: 9, 10 or 11 repeats; other, alleles with 4--8, 12--15 repeats.

Comparison between (CAG)~9~ repeats and other types repeats performed by the Review Manager software; OR: odds ratio; 95%CI: 95% confidence interval.

Closely following the (CAG)~n~ polymorphism was the CCG triplet repeats varying between 4 and 5 proline tandem repeats (*P~4~* or *P~5~*). More than 95% of individuals in both CAD patients and NCA controls contained five prolines, and the frequencies of (CCG)~n~ allele and genotypes yielded no significant differences between two groups (data not shown). Additionally, a CCA deletion resulting in lack of one proline amino acid, located adjacent to (CCG)~n~ site, was detected only in one unaffected subject.

Interestingly, the 21-bp deletion was found only in five independent CAD patients, and none in NCA subjects. In this cohort, they all had some traditional CAD risk factors, including dyslipidemia, hypertension and family history of cardiovascular diseases; three showed severe lesion in the left main coronary artery and two were diagnosed with premature CAD. After a 5-year follow up, one died of sudden cardiac death, one took stent treatment and three underwent coronary artery bypass grafting ([Table S2](#pone.0031406.s003){ref-type="supplementary-material"}).

Besides the aforementioned four variants, we identified three synonymous SNPs (A1299G, G1305A, and G1353T) and one non-synonymous SNP (C1303T) in exon 11. The A1299G and C1303T polymorphisms were rare SNPs with minor allele frequencies being 0.1% and 0.4% among NCA controls, respectively. As a result, none of these four SNPs were associated with CAD (data not shown).

After dropping four rare variations (21-bp deletion, CCA deletion, A1299G and C1303T polymorphisms), we evaluated the remaining four common variants for further haplotype analysis. Using the most common haplotype (Q)~9~-*P~5~*-G-T (in order of (CAG)~n~, (CCG)~n~, G1305A and G1353T) (26.0% in NCA controls) as the baseline for the comparison of the rest, the differences in haplotype distributions between the two groups did not achieve nominal significance (data not shown).

Meta-analysis results of (CAG)~n~ polymorphism {#s3c}
----------------------------------------------

The initial search strategy retrieved forty-three relevant articles in English (n = 24) and Chinese (n = 19), in which the effect of *MEF2A* gene variations on CAD was evaluated. A total of fifteen studies met selection criteria, whereas only eight studies [@pone.0031406-Gonzlez1], [@pone.0031406-Han1], [@pone.0031406-Weng1]--[@pone.0031406-Dai1], [@pone.0031406-Yuan1]--[@pone.0031406-Lieb1] were tailored to the inclusion criteria in the meta-analysis because six [@pone.0031406-Elhawari1], [@pone.0031406-Kajimoto1], [@pone.0031406-Guella1], [@pone.0031406-Horan1]--[@pone.0031406-Wu1] lacked the necessary information on (CAG)~n~ genotypes/alleles, and one shared the same population [@pone.0031406-Dai1], [@pone.0031406-Dai2]. Twenty-five studies, including fourteen review papers, comments and editorials, and fourteen relating to other diseases or polymorphisms in MEF2A gene, were excluded for the final analysis. The flow chart of study selection was summarized in [Figure 1](#pone-0031406-g001){ref-type="fig"}. Therefore, data from nine studies, including the present study, totaling 3801 CAD patients and 4020 controls were finally identified in the meta-analysis. Of these, five studies were carried out on Chinese (including this study, 61.85%) [@pone.0031406-Han1], [@pone.0031406-Hsu1], [@pone.0031406-Dai1], [@pone.0031406-Yuan1], three on Whites (36.16%) [@pone.0031406-Gonzlez1], [@pone.0031406-Weng1], [@pone.0031406-Lieb1] and one on Turks (1.99%) [@pone.0031406-Gulec1].

![Flow chart of studies identified through the systematic literature search.](pone.0031406.g001){#pone-0031406-g001}

![The comparison of the MEF2A (CAG)~9~ allele versus other alleles (with 4--8, 10--15 repeats) under a random effects model.](pone.0031406.g002){#pone-0031406-g002}

The demographics and clinical features of all eligible studies are summarized in [Table 2](#pone-0031406-t002){ref-type="table"}. The sample sizes ranged from 156 to 2061. The percentage of males ranged from 72.4% to 87.4% in CAD patients and 49.4% to 79.8% in controls. The mean age was greater than 56 years old in CAD patients and 51 in controls. All studies had allele data of (CAG)~n~ polymorphism except for two with only genotype counts [@pone.0031406-Han1], [@pone.0031406-Gulec1]. Seven studies provided information on this polymorphism associated with CAD/MI, and two with MI only [@pone.0031406-Gulec1], [@pone.0031406-Lieb1]. The (CAG)~9~ allele frequency differed widely in diverse ethnic groups. In Whites, the frequencies were in the ranges of 32.2% to 36.2% for CAD cases and 30.6% to 36.3% for controls, which were lower than that in Chinese ranging from 24.3% to 40.5% for cases and 22.7% to 41.8% for controls. In contrast, the Turks had a higher frequency of 51% for cases and 33.5% for controls ([Table 2](#pone-0031406-t002){ref-type="table"}).

As shown in [Figure 2](#pone-0031406-g002){ref-type="fig"}, compared with other tandem repeats carriers, those with the (CAG)~9~ allele yielded a non-significant 15% increased risk for CAD (95% CI = 0.97--1.37, *P* = 0.1) under a random-effects model. Whereas, of nine studies, only two individual OR estimates showed a higher risk of CAD that was statistically significant for (CAG)~9~ allele compared with other alleles (Han et al.: OR = 1.96, 95% CI = 1.55--2.47, *P*\<0.001; Gulec et al.: OR = 2.06, 95% CI: 1.30--3.26, *P* = 0.002, respectively).

However, statistically significant heterogeneity was evident in most subgroups, according to covariates identified by our qualitative assessment ([Table 3](#pone-0031406-t003){ref-type="table"}). In view of genotyping methods, we classified the nine studies into sequence (including this study) [@pone.0031406-Gonzlez1], [@pone.0031406-Weng1], [@pone.0031406-Dai1]/other (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, MALDI-TOF MS) [@pone.0031406-Hsu1] and PCR-SSCP (single-strand conformational polymorphism analysis) [@pone.0031406-Han1], [@pone.0031406-Yuan1]--[@pone.0031406-Lieb1] groups. There was no significant heterogeneity in the sequence/other group (OR = 1.00, 95% CI: 0.90--1.11; *P~heterogeneity~* = 0.25). In comparison, studies in PCR-SSCP group were heterogeneous (OR = 1.41, 95% CI: 0.94--2.12; *P~heterogeneity~*\<0.00001). However, differences in *MEF2A* genotyping methods did not affect the overall results materially.

10.1371/journal.pone.0031406.t003

###### Meta-analysis of the effect of (CAG)~9~ allele on CAD risk according to potential sources of heterogeneity.

![](pone.0031406.t003){#pone-0031406-t003-3}

                           Studies (cases/controls), N (n/n)      (CAG)~9~ repeats carriers      
  ----------------------- ----------------------------------- ---------------------------------- ----------------
  Genotyping methods                                                                             
  Sequence/other                     5 (2636/2167)             0.07, 1.00 \[0.90, 1.11\], 0.94      26%, 0.25
  PCR-SSCP                           4 (1165/1853)             1.66, 1.41 \[0.94, 2.12\], 0.10    90%, \<0.00001
  Control selection                                                                              
  Symptom investigation              5 (1368/2132)             1.24, 1.13 \[0.93, 1.38\], 0.21      68%, 0.01
  Normal angiography                 4 (2433/1888)             0.90, 1.16 \[0.84, 1.61\], 0.37    90%, \<0.00001
  Ethnic                                                                                         
  White                              3 (1041/1787)             0.22, 0.99 \[0.88, 1.11\], 0.82       0%, 0.62
  Chinese                            5 (2691/2146)             1.22, 1.18 \[0.90, 1.54\], 0.22    88%, \<0.00001
  Turk                                 1 (69/87)               3.08, 2.06 \[1.30, 3.26\], 0.002        N/A

CAD: coronary artery disease; PCR: polymerase chain reaction; SSCP: single strand conformational polymorphism analysis.

After stratification by control selection criteria based on clinical symptoms or coronary angiographic data, significant heterogeneity was observed in both the NCA group and the symptom investigation group (*P~heterogeneity~* = 0.01 and \<0.00001, respectively). Moreover, negative associations persisted across all comparisons.

We divided the population into three groups by ethnicity, Chinese (including this study) [@pone.0031406-Han1], [@pone.0031406-Hsu1], [@pone.0031406-Dai1], [@pone.0031406-Yuan1], White (Spanish, German and Canadian) [@pone.0031406-Gonzlez1], [@pone.0031406-Weng1], [@pone.0031406-Lieb1] and Turk [@pone.0031406-Gulec1]. Although, there was no evidence of heterogeneity in White population (OR = 0.99, 95% CI: 0.88--1.11; *P~heterogeneity~* = 0.62), it was significant in Chinese population possibly due to the wide spectrum of (CAG)~9~ allele (OR = 1.18, 95% CI: 0.90--1.54; *P~heterogeneity~*\<0.00001). Since there was only one study performed in Turks with a relatively small sample size (n = 156), the risk estimate showed a significant higher risk of (CAG)~9~ allele with CAD (*P* = 0.002), and there was no difference in the pooled risk estimates.

To assess publication bias, we calculated the fail safe number (N*~fs~*) at the level of 0.05 for each comparison. The N*~fs0.05~* values for all the comparisons were greater (62.63) than the number of studies (n = 9) included in this meta-analysis. Therefore, no evidence showed publication bias for association between *MEF2A* gene (CAG)~n~ polymorphism and CAD susceptibility.

Systematic review of the 21-bp deletion {#s3d}
---------------------------------------

Of the forty-three potentially relevant studies and the present study, fourteen were eligible for a systematic review of the 21-bp deletion and CAD risk, and thirty studies were excluded ([Figure 1](#pone-0031406-g001){ref-type="fig"}). Three of these were family-based studies and the remaining eleven used a hospital-based case-control design ([Table 4](#pone-0031406-t004){ref-type="table"}). Of the latter, four studies (including this study) [@pone.0031406-Han1], [@pone.0031406-Dai1], [@pone.0031406-Maiolino1] had used coronary angiography as critical criteria for classification the enrollments, and four studies (including this study) involved more than 1000 subjects in controls [@pone.0031406-Gonzlez1], [@pone.0031406-Weng1], [@pone.0031406-Guella1]. Seven studies were conducted on Whites (53.85%) [@pone.0031406-Wang1], [@pone.0031406-Gonzlez1], [@pone.0031406-Weng1], [@pone.0031406-Guella1], [@pone.0031406-Lieb1], [@pone.0031406-Horan1], [@pone.0031406-Maiolino1], six on East Asian populations (including this study, 38.46%) [@pone.0031406-Han1], [@pone.0031406-Kajimoto1], [@pone.0031406-Hsu1], [@pone.0031406-Dai1], [@pone.0031406-Li1] and one on Turks (7.69%) [@pone.0031406-Gulec1]. The frequency of the 21-bp deletion in sporadic patients differed substantially, from 0.09% to 1.92%, mainly 0.16% in Whites [@pone.0031406-Guella1], [@pone.0031406-Maiolino1] and 0.65% in Asian (including this study) [@pone.0031406-Kajimoto1], [@pone.0031406-Dai1], [@pone.0031406-Li1], all were less than 5%. Two studies on Whites [@pone.0031406-Weng1], [@pone.0031406-Guella1] and one on Japanese [@pone.0031406-Kajimoto1] confirmed the 21-bp deletion in controls (not angiographically tested), and the frequency was 0.12% and 0.51%, respectively. The overall frequency of the 21-bp deletion was approximately 0.2% in the combined populations of studies published to date.

10.1371/journal.pone.0031406.t004

###### Systematic review of the association between 21-bp deletion and CAD/MI.

![](pone.0031406.t004){#pone-0031406-t004-4}

  Ref. no            Study                    Ethnicity              Study design      Genotyping methods                        Study size                                                              21-bp deletion                                                                                                                                                                                                                              
  --------- ------------------------ --------------------------- -------------------- -------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  11           Wang et al. (2003)         White (American)        family-based study        Sequence                    a single large CAD/MI family                in all ten living CAD/MI members (3 female, 6 with MI, 3 with CABG, 1 with premature MI)                                                                                                                                                                                         
  16         Kajimoto et al. (2005)       Asian (Japanese)        case-control study        Sequence                               379 MI                                                                     589                                                                                                                              3, no detailed data                                                                                                                                                       3, not angiographically tested
  17           Weng et al. (2005)         White (Canadian)        case-control study        Sequence                          300 premature CAD                                                               1821                                                                                                                                     none                                                                                           3 elderly subjects in a 71-year-old female kindred; a 45-year-old obese male with diabetes; a 45-year-old normal-weight male; all of them not angiographically tested
  13         González et al. (2006)        White (Spanish)        case-control study        Sequence                               483 MI                                                                     1189                                                                                                                           none in any individuals                                                                                 
  34          Horan et al. (2006)           White (Irish)         family-based study        Sequence        1481 individuals from 573 families with premature CAD                                   none in any individuals                                                                                                                                                                                                                          
  39            Li et al. (2006)      Asian (Northern Chinese )   case-control study        PCR-SSCP                             156 CAD/MI                                                                    93                                              a 40-year-old male; a 69-year-old male with dyslipidemia, family history of CAD and diabetes; a 50-year-old male with dyslipidemia and smoking; all of them had three-vessel disease                                                                                   none
  14           Han et al. (2007)      Asian (Northern Chinese)    case-control study        PCR-SSCP                               378 CAD                                                                    348                                                                                                                            none in any individuals                                                                                 
  32          Gulec et al. (2008)               Turk              case-control study        PCR-SSCP                           69 premature MI                                                                 87                                                                                                                            none in any individuals                                                                                 
  33           Lieb et al. (2008)          White (German)         family-based study        PCR-SSCP           23 representative individuals with familial MI                                                 none                                                                                                                                                                                                                                   
  18           Hsu et al. (2009)          Asian (Taiwanese)       case-control study      MALDI-TOF MS                           258 CAD/MI                                                                   258                                                                                                                                      none                                                                                          
  20          Guella et al. (2009)         White (Italian)        case-control study        Sequence                             3127 CAD/MI                                                                  3083                                                                                                    5 obese males with premature MI (4 with smoking, 2 with dyslipidemia)                                                                                                                     a 55-year-old woman, not angiographically tested
  19           Dai et al. (2010)      Asian (Northern Chinese)    case-control study        PCR-SSCP                               257 CAD                                                                    154                                                                                                                              1, no detailed data                                                                                                                                                                    none
  38         Maiolino et al. (2011)        White (Italian)        case-control study     FRET and HRMA                            1079 CAD                                                                    301                                                                              a 52-year-old male with early onset three vessels CAD, hypertension, smoking, family history of MI and sudden death                                                                                                                    none
                   This study         Asian (Southern Chinese)    case-control study        Sequence                              1045 CAD                                                                    1008                                                                                                      5, more details in [table 3](#pone-0031406-t003){ref-type="table"}                                                                                                                                            none

CAD: coronary artery disease; MI: myocardial infarction; PCR: polymerase chain reaction; SSCP: single strand conformational polymorphism analysis; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; FRET: fluorescence resonance energy transfer technology; HRMA: high resolution melting analysis.

As shown in [Table 4](#pone-0031406-t004){ref-type="table"}, more than half of patients bearing the deletion either suffered severe CAD who had undergone percutaneous coronary intervention or coronary artery bypass grafting, or had some traditional CAD risk factors, such as hypertension, diabetes, dyslipidemia, smoking, drinking, and/or family history of CAD/MI or sudden death. But, the results of different studies were inconsistent. Hsu et al. [@pone.0031406-Hsu1], [@pone.0031406-Lieb1] failed to detect this rare variant in CAD patients. In contrast, Weng et al. [@pone.0031406-Weng1] discovered this deletion in unaffected individuals rather than in CAD patients. However, Kajimoto et al. [@pone.0031406-Kajimoto1], [@pone.0031406-Guella1] reported this variant in both CAD patients and controls, and González et al. [@pone.0031406-Gonzlez1], [@pone.0031406-Han1], [@pone.0031406-Gulec1], [@pone.0031406-Horan1] did not reveal this deletion in any subject of the study population.

Discussion {#s4}
==========

In the present study, we verified eight variants in *MEF2A* exon 11 and found that the most conspicuously heterogeneous variant was the (CAG)~n~ polymorphism, while the other seven were all downstream of this polymorphism within 100 bp. Such intense variation in the context of a single exon led us to explore the link of *MEF2A* genetic polymorphisms to CAD/MI. A possible explanation might be the remarkable diversity embedded in (CAG)~n~ polymorphism. We therefore carried out a rigorously-designed case-control association study focusing on *MEF2A* exon 11 in southern Chinese and reviewed all available information regarding the relationship between this genetic hotspot and sporadic CAD/MI from the literature. To the best of our knowledge, this is the first meta-analysis seeking to clarify the association of *MEF2A* gene (CAG)~n~ polymorphism with CAD risk.

Data from our case-control study, which was in concordance with most previous observations, and in combination with all other eight studies involving a total of 3801 CAD patients and 4020 controls, failed to show a significant association between (CAG)~n~ polymorphism and CAD susceptibility, even upon stratification by race (mainly Whites and Chinese). This meta-analysis had sufficient statistical power [@pone.0031406-Cardon1] to detect such genetic effect. Therefore, it is reasonable to surmise that either (CAG)~n~ polymorphism itself exhibits null association with CAD, or its effect on CAD is small and depends on neighboring variants that compensate or dilute the variation under study.

Noteworthy, one study conducted by Han et al. [@pone.0031406-Han1] in a small northern Chinese cohort showed a positive and independent association of (CAG)~9~ allele with an increased risk and severity of CAD, while data from Dai et al. [@pone.0031406-Dai1] in another 1139 northern Chinese cohort displayed a marginal significance (P = 0.052). However, in our present study, we failed to replicate this association in southern Chinese, which was in line with two other Chinese populations [@pone.0031406-Hsu1], [@pone.0031406-Yuan1] and in agreement with the pooled estimate of this meta-analysis. Except for the differences in diet and climate between northern and southern China, this discrepancy might be caused by misgenotyping as discussed by Hsu et al. [@pone.0031406-Hsu1]. All participants in Han\'s study were homozygous for (CAG)~n~ polymorphism; the phenomenon was not compatible with the situation expected from random mating. After separating analyses by genotyping methods, we found that heterogeneity between studies in the PCR-SSCP group was higher than the overall estimate; however, there was no indication attributable to the diversity between different experimental methods. Nevertheless, applying appropriate genotype techniques remain an open question.

Moreover, it is well known that CAD is frequently asymptomatic and the diagnosis relies on coronary angiography. However, the definition of controls was debatable in a number of the available studies. Some controls were enrolled according to their clinical symptoms and should have been properly defined as "uncertain phenotype" [@pone.0031406-Wang2], whereas some were on the basis of explicit coronary angiographic results. Thus we cannot exclude the possibility that the apparently healthy elderly controls had underlying CAD, and so confuse and bias the study conclusions. Therefore, our meta-analysis pinpointed the different selective criteria of controls as a potentially significant source of between-study heterogeneity. Nevertheless, deviation in the controls did not appear to be a significant source of between-study heterogeneity. Although this observation seems counterintuitive in terms of selective criteria, considering the relative small sample sizes even in the present meta-analysis and the possibility that (CAG)~n~ polymorphism might not be a major contributing locus or have limited values to assess an exact role of *MEF2A* in CAD/MI, we maintain that application of coronary angiographic criteria for controls is preferable, and the proper phenotype discrimination is critical in any genetic association study.

Meanwhile, we observed the wide divergence of (CAG)~n~ repeats across different populations. Specifically, the high versus low frequency of (CAG)~9~ allele was nearly double in both CAD patients and controls, suggesting a possible role of differences in genetic background and the environment in which the populations live. Of note, there was only one eligible Turkish population [@pone.0031406-Gulec1], and there was statistical evidence of heterogeneity between subgroups only in this population. It was likely that this positive association between the (CAG)~9~ allele and CAD in the Turkish study might be due to chance or confounding, for its sample size was rather small (n = 156) and its deviation would have little or no effect on our null results. We agree that more studies in diverse ethnic/racial groups are required to draw a firm conclusion.

It was noteworthy that we identified the 21-bp deletion only in affected individuals, which was consistent with the results from Wang et al. [@pone.0031406-Wang1], [@pone.0031406-Dai1], [@pone.0031406-Maiolino1], [@pone.0031406-Li1], but which are contradicted by observations in other [@pone.0031406-Gonzlez1], [@pone.0031406-Han1], [@pone.0031406-Kajimoto1]--[@pone.0031406-Hsu1], [@pone.0031406-Guella1], [@pone.0031406-Gulec1]--[@pone.0031406-Horan1]. Considering that the 21-bp deletion was firstly identified in an exceptional CAD family displaying an autosomal-dominant pattern of inheritance and no families in the specific context were ever available for genetic linkage analysis thus far, the molecular case-control association studies of unrelated samples have become the alternative research strategy, but the results were inconsistent. Researchers have argued strongly against this deletion as a causal variant in the mechanisms of CAD pathopoiesis [@pone.0031406-Wang2], [@pone.0031406-Altshuler1]. In view of possibly different genetic profiles and clinical features, we cannot jump to a conclusion regarding the cosegregation of the 21-bp deletion with CAD until validation in well-designed, large cohort studies. On the other hand, the susceptibility of patients with the 21-bp deletion to CAD supports the common-disease rare-variant (minor allele frequency less than 5%) hypothesis (CDRV) rather than the common-disease common-variant hypothesis (CDCV) [@pone.0031406-Evans1], [@pone.0031406-Schork1]. There exists a 'common-variant, small-effect' model and also the possibility of a 'rare-variant, large-effect' model [@pone.0031406-Horan1], the question is not which model is correct, but rather what is the relative contribution of each [@pone.0031406-Evans1], [@pone.0031406-Iyengar1]--[@pone.0031406-Panagiotou1]. Although our findings add potent evidence favoring the association of the 21-bp deletion with CAD, the possibility of a founder effect from a common variant, such as (CAG)~n~ polymorphism, cannot be ruled out. The challenge here is to decide which observed variants in *MEF2A* gene could be considered as a susceptibility or causal mutation in CAD. Our data indicate that the rare 21-bp deletion might have a more compelling effect on CAD than the common (CAG)~n~ variant, and *MEF2A* genetic variants might, therefore, be a rare but specific cause of CAD/MI. Needless to say, a composite effect encompassing all influential *MEF2A* genetic variants remains to be determined.

Finally, some limitations of this study should be acknowledged when interpreting the results. Firstly, it is recognized that differences in study design, genetic heterogeneity and statistical methods made it harder to estimate the exact underlying genetic contribution to disease susceptibility. Moreover, some large-scale studies [@pone.0031406-Elhawari1], [@pone.0031406-Guella1], [@pone.0031406-Horan1] could not be included in our meta-analysis because of their incomplete raw data. These could have potentially introduced additional factors and influenced our results. Secondly, most of the enrolled study samples, including our affected population, were all survivors of CAD, as we could not evaluate those who did not survive. Thirdly, considering the complex interplay between the *MEF2A* gene and others that operate in the same pathway, the single-locus based case-control study and meta-analysis preclude the possibility of gene-gene and gene-environment interactions and may not reveal the full picture. Although there was no evidence showing publication bias in our overall meta-analysis, considering the above limitations, further studies with larger sample size and different ethnic compositions, which typically considered as small or moderate effects, are warranted to avoid study bias.

In conclusion, our case-control study and the following meta-analysis provide no convincing evidence for the genetic involvement of *MEF2A* gene (CAG)~n~ polymorphism in CAD. However, we suggested that the 21-bp deletion might be a rare but specific cause of CAD. As few studies are available in this field and current evidence remains limited, this conclusion requires further confirmation by well-designed prospective studies with adequate methodological quality and properly controlling for possible confounds, particularly different genetic approaches, homogeneous CAD patients and well-matched controls, gene-gene and gene-environment interactions, and multiethnic groups.
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